Clinical trial
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone…
NCT00390468 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00390468 |
|---|---|
| Title | Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases |
| Official title | A Phase II Study of Tandutinib (MLN518) in Androgen-Independent Prostate Cancer With Bone Metastases |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Cancer, Pain, Prostate Cancer |
| Intervention type | Drug |
| Interventions | Tandutinib |
| Enrollment | 18 |
| Start date | Oct 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Oct 19, 2006 |
| Last update posted | May 28, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: